These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2012757)

  • 1. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance.
    Archimbaud E; Bailly M; Doré JF
    Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of LAK cells in vitro in patients with acute leukemia.
    Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
    Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphokine-activated killer cytotoxicity against leukaemic blast cells.
    Tratkiewicz JA; Szer J; Boyd RL
    Clin Exp Immunol; 1990 Apr; 80(1):94-9. PubMed ID: 2323104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
    Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
    Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
    Foa R; Fierro MT; Cesano A; Guarini A; Bonferroni M; Raspadori D; Miniero R; Lauria F; Gavosto F
    Blood; 1991 Aug; 78(4):1041-6. PubMed ID: 1868239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
    Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
    Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
    Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
    Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
    Verfaillie C; Kay N; Miller W; McGlave P
    Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells.
    Notter M; Ludwig WD; Bremer S; Thiel E
    Blood; 1993 Nov; 82(10):3113-24. PubMed ID: 7693036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation are donor-derived.
    Boughton BJ; Simpson AW; Phaure TA; Beatty C
    Cancer Immunol Immunother; 1995 Jul; 41(1):68-70. PubMed ID: 7641221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells.
    Panayotides P; Porwit A; Sjögren AM; Wasserman J; Reizenstein P
    Eur J Haematol; 1988 Apr; 40(4):362-7. PubMed ID: 3259192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of adherent lymphokine activated killer (A-LAK) cells from patients with acute myelogenous leukaemia.
    Sedlmayr P; Rabinowich H; Winkelstein A; Herberman RB; Whiteside TL
    Br J Cancer; 1992 Feb; 65(2):222-8. PubMed ID: 1739621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2 induction of lymphokine-activated killer activity in the peripheral blood of an acute lymphoblastic leukaemia patient--case study.
    Dickinson AM; Lennard AL; Cartner R; Proctor SJ
    Leukemia; 1992 Sep; 6(9):957-60. PubMed ID: 1518307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease.
    Boughton BJ; Simpson AW
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):1-6. PubMed ID: 10390074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG; Zeuthen J; Claësson MH
    Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells.
    Teichmann JV; Ludwig WD; Thiel E
    Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.